[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343642-105":59,"doc-detail-343642-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","advances-and-challenges-in-the-use-of-liquid-biopsy-in-gynaecological-oncology-review-article","Advances and challenges in the use of liquid biopsy in gynaecological oncology - Review article","","Ovarian cancer, endometrial cancer, and cervical cancer threaten women’s health worldwide, making improved detection and monitoring essential for earlier diagnosis and better prediction of recurrence. Conventional surveillance relies on imaging and limited blood protein biomarkers, and tissue sampling is invasive and poorly suited for screening and longitudinal assessment. Liquid biopsy examines tumour-derived blood components such as ctDNA, CTCs, cfRNA, TEPs, and exosomes, offering non-invasive, practical, repeatable monitoring that can support prognosis, relapse detection, and therapy response.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/advances-and-challenges-in-the-use-of-liquid-biopsy-in-gynaecological-oncology-review-article/343642/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/advances-and-challenges-in-the-use-of-liquid-biopsy-in-gynaecological-oncology-review-article/343642.png","ImageObject",300,407,{"name":92,"@type":93},"Skyler","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is liquid biopsy relevant for gynaecological oncology surveillance?","Question",{"text":113,"@type":114},"It enables minimally invasive, real-time monitoring of tumour changes over time, supporting early diagnosis, prognosis, recurrence detection, and therapy response tracking.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which tumour components are typically analyzed in liquid biopsy?",{"text":118,"@type":114},"Common components include circulating tumour DNA (ctDNA), circulating tumour cells (CTCs), cell-free RNA (cfRNA), tumour-educated platelets (TEPs), and exosomes, along with other circulating biomolecules mentioned in the review.",{"name":120,"@type":111,"acceptedAnswer":121},"What limits conventional biopsy methods in this setting?",{"text":122,"@type":114},"Conventional biopsy is invasive and has limited ability to capture tumour heterogeneity, making it less suitable for continuous, longitudinal monitoring.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},343642,1790824734,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":24,"preview_urls":147},2336464648746,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Heliyon 10 (2024) e39148  \nContents lists available at ScienceDirect  \nHeliyon  \njournal [homepage:](homepage: www.cell.com/heliyon)[ www.cell.com/heliyon](homepage: www.cell.com/heliyon)  \n| Review article\u003Cbr>Advances and challenges in the use of liquid biopsy ingynaecological oncology\u003Cbr>*\u003Cbr>Yingfeng Zhang , Libi Tian\u003Cbr>University-Town Hospital of Chongqing Medical University, Chongqing, 401331, China |  |  |\n| --- | --- | --- |\n| A R T I C L E I N F O |  | A B S T R A C T |\n| Keywords: Gynaecological cancers Liquid biopsy\u003Cbr>ctDNA CTCs cfRNATEPs Exosomes |  | Ovarian cancer, endometrial cancer, and cervical cancer are the three primary gynaecological cancers that pose a significant threat to women’s health on a global scale. Enhancing global cancer survival rates necessitates advancements in illness detection and monitoring, with the goal of improving early diagnosis and prognostication of disease recurrence. Conventional methods for identifying and tracking malignancies rely primarily on imaging techniques and, when possible, protein biomarkers found in blood, many of which lack specificity. The process of collecting tumour samples necessitates intrusive treatments that are not suitable for specific purposes, such as screening, predicting, or evaluating the effectiveness of treatment, monitoring the presence of remaining illness, and promptly detecting relapse. Advancements in treatment are being made by the detection of genetic abnormalities in tumours, both inherited and acquired. Newly designed therapeutic approaches can specifically address some of these abnormalities. Liquid biopsy is an innovative technique for collecting samples that examine specific cancer components that are discharged into the bloodstream, such as circulating tumour DNA (ctDNA), circulating tumour cells (CTCs), cell-free RNA (cfRNA), tumour-educated platelets (TEPs), and exosomes. Mounting data indicates that liquid biopsy has the potential to improve the clinical management of gynaecological cancers through enhanced early diagnosis, prognosis prediction, recurrence detection, and therapy response monitoring. Understanding the distinct genetic composition of tumours can also inform therapy choices and the identification of suitable targeted treatments. The main benefits of liquid biopsy are its non-invasive characteristics and practicality, enabling the collection of several samples and the continuous monitoring of tumour changes over time. This review aims to provide an overview of the data supporting the therapeutic usefulness of each component of liquid biopsy. Additionally, it will assess the benefits and existing constraints associated with the use of liquid biopsy in the management of gynaecological malignancies. In addition, we emphasise future prospects in light of the existing difficulties and investigate areas where further research is necessary to clarify its rising clinical capabilities. |\n\n1. Liquid biopsy  \nThe prevailing trajectory in the field of oncology is shifting towards the use of minimally invasive methodologies for the timely identification, continuous surveillance, and prognostication of therapeutic outcomes in individuals afflicted with cancer [1]. The present approaches employed for the analysis and surveillance of gynaecological malignancies predominantly depend on conventional  \n* Corresponding author.  \nE-mail addresses: [1137178282@qq.com](1137178282@qq.com) (Y. Zhang), [fengwonderful@sina.com](fengwonderful@sina.com) (L. Tian).  \n[https://doi.org/10.1016/j.heliyon.2024.e39148](https://doi.org/10.1016/j.heliyon.2024.e39148)  \nReceived 21 May 2024; Received in revised form 8 October 2024; Accepted 8 October 2024 Available online 15 October 2024  \n2405-8440/© 2024 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)).  \nbiopsy, an invasive technique that plays a crucial role in the d","cbCaib9KH9dKtZDq","https://ap.wps.com/l/cbCaib9KH9dKtZDq","pdf",8259441,45,"English","# Liquid biopsy\n## Clinical context: minimally invasive surveillance\n## Precision and personalised oncology with circulating biomarkers","[{\"question\":\"Why is liquid biopsy relevant for gynaecological oncology surveillance?\",\"answer\":\"It enables minimally invasive, real-time monitoring of tumour changes over time, supporting early diagnosis, prognosis, recurrence detection, and therapy response tracking.\"},{\"question\":\"Which tumour components are typically analyzed in liquid biopsy?\",\"answer\":\"Common components include circulating tumour DNA (ctDNA), circulating tumour cells (CTCs), cell-free RNA (cfRNA), tumour-educated platelets (TEPs), and exosomes, along with other circulating biomolecules mentioned in the review.\"},{\"question\":\"What limits conventional biopsy methods in this setting?\",\"answer\":\"Conventional biopsy is invasive and has limited ability to capture tumour heterogeneity, making it less suitable for continuous, longitudinal monitoring.\"}]","Advances and challenges in the use of liquid biopsy in gynaecological oncology - Review article | PDF",1790051659,113,[148,152,156,160,164],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/af783dd2e0eaa1d44c86a0e9ae0071d6.webp",983,1341,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4d500319b4cb63fcb569df617978e37c.webp",982,1340,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/30af15a67e2ef9f7b0ca5df9ab655127.webp",981,1338,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/80baf474a07f804b2314b15df096cfd5.webp",980,1337,{"page_no":24,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ede2a62bd5cee9b806e2ea57cb580b9c.webp",979,1336]